225 results If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines. Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement. Stibbe advises Jumbo family Van Eerd on acquisition of Hema Stibbe advised Mississippi Ventures, the investment vehicle of the Van Eerd family (owners of supermarket chain Jumbo), on the acquisition of the remaining 50 per cent of the shares in HEMA. Stibbe adviseert Jumbo-familie Van Eerd bij overname HEMA Stibbe heeft Mississippi Ventures, het investeringsvehikel van de familie Van Eerd (eigenaar van supermarktketen Jumbo), geadviseerd bij de overname van de overige 50 procent van de aandelen in HEMA. Stibbe advises Seven2 Stibbe advised Seven2 on the acquisition of a majority stake in Zwart Techniek. Belgian Competition Authority confirms jurisdiction for M&A transactions in hospital sector On 14 July 2023, the Belgian Competition Authority confirmed its jurisdiction to review M&A transactions between hospitals, regardless of whether these hospitals belong to the same hospital network. The era of FDI screenings kicks off in Belgium The Belgian screening mechanism for FDIs will enter into force on 1 July 2023. The mechanism is designed to safeguard Belgium's critical infrastructure and to protect sectors crucial to Belgium's public order, national security and strategic interests. Extended access to electronic data for the Belgian Competition Authority The Belgian legislator has amended some competition law provisions in Book IV Code of Economic law. The new provision on access to data of electronic communications operators endows the Belgian Competition Authority with new investigation powers. Pagination Previous page Page 10 Page 11 Page 12 Current page 13
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.
Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement.
Stibbe advises Jumbo family Van Eerd on acquisition of Hema Stibbe advised Mississippi Ventures, the investment vehicle of the Van Eerd family (owners of supermarket chain Jumbo), on the acquisition of the remaining 50 per cent of the shares in HEMA.
Stibbe adviseert Jumbo-familie Van Eerd bij overname HEMA Stibbe heeft Mississippi Ventures, het investeringsvehikel van de familie Van Eerd (eigenaar van supermarktketen Jumbo), geadviseerd bij de overname van de overige 50 procent van de aandelen in HEMA.
Stibbe advises Seven2 Stibbe advised Seven2 on the acquisition of a majority stake in Zwart Techniek.
Belgian Competition Authority confirms jurisdiction for M&A transactions in hospital sector On 14 July 2023, the Belgian Competition Authority confirmed its jurisdiction to review M&A transactions between hospitals, regardless of whether these hospitals belong to the same hospital network.
The era of FDI screenings kicks off in Belgium The Belgian screening mechanism for FDIs will enter into force on 1 July 2023. The mechanism is designed to safeguard Belgium's critical infrastructure and to protect sectors crucial to Belgium's public order, national security and strategic interests.
Extended access to electronic data for the Belgian Competition Authority The Belgian legislator has amended some competition law provisions in Book IV Code of Economic law. The new provision on access to data of electronic communications operators endows the Belgian Competition Authority with new investigation powers.